Parkinson's Disease Market Poised for Expansion During the Forecast Period (2026-2036) Amid JUVMO Approval and Emerging Therapeutic Innovations | DelveInsight
The Parkinson's disease market is expected to grow steadily, driven by the recent approval of AbbVie's JUVMO along with the rising prevalence of the disease, particularly among the aging population. Increasing disease awareness, improved diagnosis, and advances in symptomatic and disease-management approaches. The development of novel therapies such as bemdaneprocel (BlueRock Therapeutics/Bayer), solengepras (Cerevance), buntanetap (Annovis Bio), prasinezumab (Roche/Prothena), and others is further strengthening the market growth.
LAS VEGAS, Oct. 6, 2026 /PRNewswire/ -- Recently published Parkinson's Disease Market Insights report includes a comprehensive understanding of current treatment practices, Parkinson's disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Parkinson's Disease Market Summary
Find out is there a cure for Parkinson's disease @ https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment
Key Factors Driving the Growth of the Parkinson's Disease Market
Shikha Bhardwaj, Associate Consultant of Forecasting & Analytics at DelveInsight, said that Novel therapies, including continuous levodopa/carbidopa delivery and cell-based approaches, could improve symptom control, reduce treatment burden, and potentially address underlying neuronal loss. These advances are likely to expand the addressable patient population and drive greater adoption of premium therapies, supporting market growth over the forecast period.
Parkinson's Disease Market Analysis
Parkinson's Disease Competitive Landscape
Some of the Parkinson's disease drugs under development include ND0612 [Levodopa/Carbidopa; Mitsubishi Tanabe Pharma (NeuroDerm)], Bemdaneprocel (BlueRock Therapeutics/Bayer), Solengepras (Cerevance), Buntanetap (Annovis Bio), Prasinezumab (Roche/Protherna), ACI-7104 (AC Immune), Rexaceract (GT-02287; Gain Therapeutics), BHV-8000 (Biohaven), AAV-GAD (MeiraGTx), and others.
Mitsubishi Tanabe Pharma's ND0612 LD/CD is an investigational drug-device combination therapy that delivers liquid levodopa/carbidopa (LD/CD) through continuous subcutaneous infusion over 24 hours per day. The therapy is currently undergoing Phase III clinical development.
BlueRock Therapeutics/Bayer's Bemdaneprocel (BRT-DA01) is an investigational stem cell-derived therapy for Parkinson's disease intended to replace dopamine-producing neurons lost during disease progression. The treatment involves the surgical implantation of dopaminergic neuron precursors into the brain, where they are expected to mature into functional dopamine-producing neurons. Bemdaneprocel received FDA Fast Track designation in 2021 and Regenerative Medicine Advanced Therapy (RMAT) designation in 2024.
Cerevance's Solengepras (CVN424) is an oral, once-daily investigational therapy for Parkinson's disease that targets the GPR6 receptor to regulate the indirect basal ganglia pathway. Designed to complement levodopa without directly modifying dopamine signaling, it may address both motor and non-motor symptoms. By helping rebalance disrupted neural pathways, solengepras could potentially alleviate dyskinesia and other motor complications associated with dopaminergic therapies.
AC Immune's ACI-7104 is an optimized formulation of the company's clinically validated predecessor anti-α-synuclein active immunotherapy. It is designed to elicit a target-specific antibody response against pathological oligomeric α-synuclein, thereby potentially limiting its spread and subsequent neurodegeneration in early Parkinson's disease. The therapy has demonstrated a robust and boostable antibody response, along with evidence of target engagement and an initial signal of clinical efficacy.
The anticipated launch of these emerging therapies are poised to transform the Parkinson's disease market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the Parkinson's disease market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about what are the most promising drugs being developed for parkinson's disease @ Parkinson's Disease Clinical Trials
Recent Developments in the Parkinson's Disease Market
Parkinson's Disease Epidemiology Segmentation
The Parkinson's disease epidemiology section provides insights into the historical and current Parkinson's disease patient pool and forecasted trends for the leading markets. In the UK, among the stage-specific diagnosed prevalent cases of Parkinson's disease, Stage III had the highest cases, with approximately 60,000, whereas Stage V had the lowest cases, 7,200 in 2025, which are expected to increase by 2036.
The Parkinson's disease treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Parkinson's Disease Market Report Metrics
Details
Study Period
2022–2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Parkinson's Disease Market Size in 2025
USD 8 Billion
Key Parkinson's Disease Companies
Mitsubishi Tanabe Pharma (NeuroDerm), BlueRock Therapeutics, Bayer, Cerevance, Annovis Bio, Roche, Protherna, AC Immune, Gain Therapeutics, Biohaven, MeiraGTx, AbbVie, Newron Pharmaceuticals, Zambon, Supernus Pharmaceuticals, Eisai, Kyowa Kirin, Acorda Therapeutics, Esteve Pharmaceuticals, Neurocrine Biosciences, BIAL, Ono Pharmaceutical, Hisamitsu Pharmaceutical, UCB, Amneal Pharmaceuticals, and others
Key Parkinson's Disease Therapies
ND0612 (Levodopa/Carbidopa), Bemdaneprocel, Solengepras, Buntanetap, Prasinezumab, ACI-7104, Rexaceract (GT-02287), BHV-8000, AAV-GAD, JUVMO, XADAGO/EQUFINA, NOURIANZ/NOURIAST, DUOPA/DUODOPA, INBRIJA, GOCOVRI, ONGENTYS, HARUROPI TAPE, NEUPRO/Rotigotine Transdermal, RYTARY, PRODUODOPA/VYALEV, CREXONT/IPX203, ONAPGO, and others
Scope of the Parkinson's Disease Market Report
Download the report to understand the top brands for proactive Parkinson's disease management @ Parkinson's Disease Treatment Market
Table of Contents
1
Parkinson's Disease Market Key Insights
2
Parkinson's Disease Market Report Introduction
3
Market Overview at a Glance
3.1
Market Share (%) Distribution of Parkinson's Disease by Therapies in 7MM in 2025
3.2
Market Share (%) Distribution of Parkinson's Disease by Therapies in 7MM in 2036
4
Methodology of Parkinson's Disease Epidemiology and Market
5
Executive Summary
6
Key Events
7
Disease Background and Overview
7.1
Introduction
7.2
Classification
7.3
Signs and Symptoms
7.4
Risk Factors
7.5
Pathophysiology
7.6
Diagnosis
7.7
Treatment
8
Epidemiology and Patient Population
8.1
Key Findings
8.2
Assumptions and Rationale: The 7MM
8.2.1
Diagnosed Prevalent Cases of Parkinson's Disease
8.2.2
Gender-specific Diagnosed Prevalent Cases of Parkinson's Disease
8.2.3
Age-specific Diagnosed Prevalent Cases of Parkinson's Disease
8.2.4
Stage-specific Diagnosed Prevalent Cases of Parkinson's Disease
8.2.5
Diagnosed Prevalent Cases of Psychosis in Parkinson's Disease
8.2.6
Diagnosed Prevalent Cases of MCI due to Parkinson's Disease
8.3
Total Diagnosed Prevalent Cases of Parkinson's Disease in the 7MM
8.4
The US
8.4.1
Total Diagnosed Prevalent Cases of Parkinson's Disease in the US
8.4.2
Gender-specific Diagnosed Prevalent Cases of Parkinson's Disease in the US
8.4.3
Age-specific Diagnosed Prevalent Cases of Parkinson's Disease in the US
8.4.4
Stage-specific Diagnosed Prevalent Cases of Parkinson's Disease in the US
8.4.5
Diagnosed Prevalent Cases of Psychosis due to Parkinson's Disease in the US
8.4.6
Diagnosed Prevalent Cases of MCI due to Parkinson's Disease in the US
8.5
EU4 and the UK
8.6
Japan
9
Patient Journey
10
Marketed Therapies
10.1
Marketed Drugs: Competitive Landscape
10.2
XADAGO/EQUFINA (Safinamide): Newron Pharmaceuticals/ Zambon/Supernus Pharmaceuticals/Eisai
10.2.1
Product Description
10.2.2
Regulatory Milestones
10.2.3
Other Development Activities
10.2.4
Clinical Trial Information
10.2.5
Safety and Efficacy
10.3
NOURIANZ/NOURIAST (Istradefylline): Kyowa Kirin
10.4
DUOPA/DUODOPA (Carbidopa and Levodopa-ES): AbbVie
10.5
INBRIJA (Levodopa): Acorda Therapeutics/Esteve Pharmaceuticals
10.6
GOCOVRI (Amantadine): Supernus Pharmaceuticals
10.7
ONGENTYS (Opicapone): Neurocrine Biosciences/BIAL/Ono Pharmaceutical
10.8
HARUROPI TAPE (Ropinirole HCL): Hisamitsu Pharmaceutical/Kyowa Kirin
10.9
NEUPRO/ Rotigotine Transdermal: UCB
10.10
RYTARY (Carbidopa and Levodopa): Amneal Pharmaceuticals
10.11
PRODUODOPA/ VYALEV (Foscarbidopa/ Foslevodopa): AbbVie
10.12
CREXONT/IPX203: Amneal Pharmaceuticals
10.13
ONAPGO: Supernus Pharmaceuticals
List to be continued in the final report.
11
Emerging Drug Profiles
11.1
Emerging Drugs: Competitive Landscape
11.2
Solengepras (CVN424): Cerevance
11.2.1
Product Description
11.2.2
Other Developmental Activities
11.2.3
Clinical Trials Information
11.2.4
Safety and Efficacy
11.2.5
Analysts' Views
11.3
Buntanetap (ANVS401/Posiphen): Annovis Bio
11.4
ND0612 (Levodopa/Carbidopa): Mitsubishi Tanabe Pharma (NeuroDerm)
11.5
Prasinezumab: Roche/Prothena
11.6
Bemdaneprocel: BlueRock Therapeutics/Bayer
List to be continued in the final report.
12
Parkinson's Disease Market Analysis
12.1
Key Findings
12.2
Key Parkinson's Disease Market Forecast Assumptions
12.3
Parkinson's Disease Market Outlook
12.4
Attribute Analysis
12.5
Total Market Size of Parkinson's Disease in the 7MM
12.6
Market Size of Parkinson's Disease by Therapies in the 7MM
12.7
The US Parkinson's Disease Market
12.7.1
Total Market Size of Parkinson's Disease in the US
12.7.2
Market Size of Parkinson's Disease by Therapies in the US
12.8
EU4 and the UK Parkinson's Disease Market
12.9
Japan Parkinson's Disease Market
13
Key Opinion Leaders' Views
14
SWOT Analysis
15
Unmet Needs
16
Market Access and Reimbursement
16.1
The US
16.2
In EU4 and the UK
16.3
Japan
17
Bibliography
18
Acronyms and Abbreviations
19
Parkinson's Disease Market Report Methodology
Related Reports
Parkinson's Disease Clinical Trial Analysis
Parkinson's Disease Pipeline – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Parkinson's disease companies, including Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., and others.
Psychosis in Parkinson's and Alzheimer's Disease Market
Psychosis in Parkinson's and Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psychosis in Parkinson's and Alzheimer's disease companies, including Sunovion Pharmaceuticals, Karuna Therapeutics, Vanda Pharmaceuticals, Suven Life Sciences, Enterin, Intra-Cellular Therapies, Merck Sharp & Dohme, and others.
Dementia-related Psychosis Market
Dementia-related Psychosis Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key dementia-related psychosis companies including Acadia Pharmaceuticals, Bristol Myers Squibb, Cognition Therapeutics, Maplight Therapeutics, Johnson & Johnson, AgeneBio, and others.
Alzheimer's Disease Market
Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer's disease companies, including Novo Nordisk, Eli Lilly, Suven Life Sciences, Bristol Myers Squibb, IGC Pharma, T3D Therapeutics, Lexeo Therapeutics, Axsome Therapeutics, Araclon Biotech S.L., Eisai, TauRx Therapeutics, GemVax & KAEL, AC Immune SA, Johnson & Johnson, Longeveron, Vaccinex, Sinaptica Therapeutics, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
SOURCE DelveInsight Business Research, LLP